Significant Ownership of EVENTIDE ASSET MANAGEMENT, LLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for EVENTIDE ASSET MANAGEMENT, LLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Peter J. Luiso - Peter J. Luiso, General Counsel
- Manager location
- Boston, MA
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow EVENTIDE ASSET MANAGEMENT, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from EVENTIDE ASSET MANAGEMENT, LLC
Significant Ownership of EVENTIDE ASSET MANAGEMENT, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| BBNX | Beta Bionics, Inc. | Common Stock, $0.0001 par value per share | 13% | $52,677,024 | +$9,643,640 | 5,945,488 | +22% | Eventide Asset Management, LLC | 31 Mar 2026 |
| OVID | Ovid Therapeutics Inc. | Common Stock, par value $0.001 per share | 7.3% | $36,787,902 | 12,773,577 | Eventide Asset Management, LLC | 31 Mar 2026 | ||
| XMTR | Xometry, Inc. | Class A Common Stock, par value $0.000001 per share | 6.7% | $78,356,159 | 3,151,897 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| Inventiva S.A. | Ordinary Shares, nominal value Euro 0.01 per share | 4.6% | 9,368,517 | -7.4% | Eventide Asset Management, LLC | 31 Dec 2025 | |||
| COLL | COLLEGIUM PHARMACEUTICAL, INC | Common Stock, par value $0.001 per share | 4.5% | $47,101,006 | -$14,946,218 | 1,424,282 | -24% | Eventide Asset Management, LLC | 31 Mar 2026 |
| MIRM | Mirum Pharmaceuticals, Inc. | Common Stock, par value $0.0001 per share | 4.1% | $165,372,042 | -$40,549,990 | 2,093,582 | -20% | Eventide Asset Management, LLC | 31 Dec 2025 |
| LXEO | Lexeo Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 3.7% | $4,544,189 | 1,234,834 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| NKTR | Nektar Therapeutics | Common Stock, $0.0001 par value | 3.6% | $4,921,000 | 6,650,000 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 3.5% | $2,353,200 | 2,220,000 | Eventide Asset Management, LLC | 31 Dec 2024 | ||
| CLDX | Celldex Therapeutics, Inc. | Common Stock, par value $0.001 | 2% | $30,459,938 | 1,356,186 | Eventide Asset Management, LLC | 30 Jun 2025 | ||
| EVH | Evolent Health, Inc. | Class A Common Stock, par value $0.01 per share | 0% | $7,109 | -$26,106,812 | 1,713 | -100% | Eventide Asset Management, LLC | 31 Dec 2025 |
| AURA | Aura Biosciences, Inc. | Common Stock, par value $0.00001 per share | 0% | $0 | -$22,524,940 | 0 | -100% | Eventide Asset Management, LLC | 31 Mar 2025 |
| ZNTL | Zentalis Pharmaceuticals, Inc. | Common Stock, $0.001 par value per share | 0% | $0 | -$6,399,327 | 0 | -100% | Eventide Asset Management, LLC | 31 Mar 2025 |
| VYNE | VYNE Therapeutics Inc. | Common Stock, par value $0.0001 | 0% | $0 | -$619,615 | 0 | -100% | Eventide Asset Management, LLC | 30 Sep 2025 |
Schedules 13D/G Reported by EVENTIDE ASSET MANAGEMENT, LLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.